Investing.com — Moderna (NASDAQ:MRNA) has revised its revenue forecast for 2025, causing a decline in the company’s share price.
The biotechnology company now expects its 2025 sales to fall between $1.5 billion and $2.5 billion.
This prediction, with a midpoint of $2 billion, falls short of the previous consensus forecast of $2.92 billion.
In response to the revised forecast, Moderna has announced that it will be stepping up its cost-cutting measures.
By the end of 2025, the company aims to have approximately $6 billion in cash. This decision to revise its revenue guidance and increase cost-cutting initiatives has led to a slump in Moderna’s shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
